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of imatinib. The anti–CD-20 antibody rituximab led the way for 
immunologic therapeutic approaches for lymphoid malignancies. The 
paradigm of targeting malignancies with increasing greater therapeu-
tic windows is being expanded by both novel agents but also novel 
delivery systems. Furthermore, the next generation of targeting agents 
affords opportunity to minimize host toxicity and increase the likeli-
hood of therapeutic response by targeting specific molecular subsets 
of a single disease. This targeted approach is personalized medicine 
at its best. This presentation will review the history of successes in 
targeted therapy and look to the future for the next generation of 
personalized approaches for hematologic malignancies.
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Summary: Health economic evaluations are central to decisions on 
the availability of new treatments and other health care interventions 
in several jurisdictions across Europe. Health technologies are not 
approved for use in the United Kingdom if they are considered to rep-
resent poor value for money; that is, if their cost-effectiveness exceeds 
around £30,000 (€ 40,000) per quality-adjusted life-year. Personalized 
medicine, in which treatments are prescribed according to patients’ 
characteristics, holds promise for more favorable health outcomes. 
However, as pharmaceutical market shares are potentially reduced as 
a consequence, there is uncertainty as to whether the compensatory 
price adjustments result in cost-effective treatment strategies. It is 
necessary, therefore, to conduct stratified cost-effectiveness analyses 
of treatments based on prognostic factors that reveal populations in 
which treatments are most likely to be effective or less likely to be 
harmful. The cost-effectiveness of pre-prescription genotyping is illus-
trated using a series of case studies: (1) HLA-B*5701 testing, which 
has dramatically reduced the incidence of hypersensitivity reactions 
to abacavir in patients with HIV; (2) VKORC1 and CYP2C9 geno-
typing to guide dose selection with warfarin; (3) HLA-A*3101 testing 
for the reduction in the incidence of carbamazepine-induced cutane-
ous adverse drug reactions; (4) testing for genetic polymorphisms in 
UGT1A1 and irinotecan-induced neutropenia and diarrhea; and (5) 
CYP2C19 testing before clopidogrel treatment in patients with acute 
coronary syndrome. With the exception of abacavir, a specific limita-
tion of these analyses, which introduces considerable uncertainty to 
the estimation of cost-effectiveness, relates to the evidential standards 
for demonstration of the clinical effectiveness of tests.
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Summary: Drug safety is an essential element for the successful oper-
ation and efficiency of any health care system. In the last decade, 
Nigeria—like most emerging countries—has put in place structures 
and mechanisms to ensure the safety of medicines used by its large 
population of ~170 million. Before this period, the focus was mainly 
on the comprehensive registration of medicines as well as ensur-
ing that good quality medicines are allowed into circulation. The 
proportion of substandard/counterfeit medicines in the market has 
decreased significantly.
In 2004, Nigeria was admitted into the WHO International Drug 
Monitoring Scheme as its 74th member after initial pharmacovigilance 
(PV) activities in a number of locations in the country. Its PV system is 
based on voluntary spontaneous reporting of adverse drug reactions. 
The operating system is the Vigiflow linked to the Uppsala Monitoring 
Centre and currently holds > 10,000 ICSRs in its local database. The 
country has recently set up a zonal (regional) PV structure with 6 cent-
ers, in consonance with its geopolitical set-up, which are linked to the 
National Pharmacovigilance Centre in the capital city Abuja. A PV pol-
icy document has just been launched to guide PV activities in the country.
The main thrust of the PV activities is the sensitization of the gen-
eral population and health care providers to raise the level of aware-
ness, as well as further advocacy of supervising regulatory bodies to 
ensure improved role of professionals and other stakeholders in PV. 
The current challenges include the engagement of the pharmaceutical 
industries, local and international, and the practitioners in herbal 
medicine. Again, coverage of the pediatric and geriatric population 
has also come into view.
In all, PV has made tremendous progress in Nigeria in the decade 
since its membership in the WHO international monitoring network.
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Most medicines in Europe are not authorized for use in children: 
almost 50% of medicines prescribed to children in the hospital are 
unlicensed for their age group or prescribed off-label. There are major 
practical and ethical issues in relation to studying medicines in chil-
dren, especially in neonates. To improve the situation, a pediatric 
regulation entered into force in 2007, and the European Medicines 
Agency identified drugs as priority medicinal products for evalua-
tion in children. The TINN project was selected by the FP7 program 
to evaluate ciprofloxacin and fluconazole. It was launched in 2008, 
and data evaluating ciprofloxacin are presented. Ciprofloxacin is a 
fluoroquinolone for the treatment of multiresistant gram-negative 
bacterial sepsis with an acceptable safety profile and a useful pattern 
of bacterial susceptibility. The TINN project included: (1) a litera-
ture review on ciprofloxacin in pediatric patients2; (2) juvenile animal 
studies using Phenopus3; and (3) a survey in Europe included 193 
NICUs from 32 countries. (4) Results showed that ciprofloxacin is 
used in 25% of NICUs, but indications and dosages vary widely4; a 
ciprofloxacin method was developed in low sample volumes5; (5) a 
population pharmacokinetic study (Liverpool, United Kingdom and 
Paris, France) included 51 neonates, showing that ciprofloxacin clear-
ance was dependent on current weight, gestational and postnatal age, 
and renal function and that volume of distribution was dependent of 
current weight6. A PIP for ciprofloxacin was not validated and no 
Paediatric-Use Marketing Authorisation (PUMA) will be obtained 
because the studies required were not possible to perform and the 
market is too small to expect viability of a new formulation. However, 
the studies conducted within TINN allow dosage recommendations to 
treat suspected or proven resistant gram-negative infections.
Project coordinated by the National Institute for Health and 
Medical Research (Prof. Evelyne Jacqz-Aigrain, FRANCE) and the 
University of Nottingham (Prof. Imti Choonara, UK) supported by 
the EC under the Health Cooperation Work Programme of the 7th 
Framework Programme.
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Summary: Acetaminophen (APAP) or paracetamol hepatotoxicity is 
the most frequent cause of acute liver failure in the United States and 
many European countries. Animal studies have shown that the small 
fraction of the dose that is metabolized by cytochrome P-450 enzymes 
leads to formation of a reactive metabolite (NAPQI), which can be 
conjugated with glutathione but also binds to proteins. Although 
protein adduct formation, especially in mitochondria, correlates with 
cell toxicity, it is insufficient to trigger cell death. Instead, the initial 
mitochondrial dysfunction causes oxidant stress, which induces activa-
tion of MAP kinases ultimately causing c-jun-N-terminal kinase (JNK) 
phosphorylation and translocation to the mitochondria where P-JNK 
amplifies the oxidant stress and peroxynitrite formation. The enhanced 
mitochondrial oxidant stress together with translocation of lysosomal 
iron causes the membrane permeability transition pore (MPT) opening, 
resulting in the collapse of the membrane potential and cessation of 
ATP synthesis. The MPT also leads to mitochondrial matrix swell-
ing, which causes the rupture of the outer membrane with release of 
endonuclease G and apoptosis-inducing factor and translocation to the 
nucleus, where these enzymes induce DNA fragmentation. The loss of 
mitochondrial function and the nuclear DNA fragmentation are key 
events in APAP-induced cell necrosis. The massive cell necrosis leads to 
the release of damage-associated molecular patterns, which, through 
activation of toll-like receptors on macrophages, trigger cytokine 
formation and leukocyte activation and recruitment. However, the 
preponderance of the experimental evidence suggests that this inflam-
matory response has limited effect on the injury but results in the 
preparation of the regenerative or repair phase.
Although there has been enormous progress in understanding 
mechanisms of APAP-induced liver injury in animals, the insight into 
the human pathophysiology is more limited. However, in both human 
hepatocytes and in overdose patients, there is emerging evidence for 
the formation of protein adducts, the central role of mitochondrial 
damage and nuclear DNA fragmentation in necrotic cell death, and 
the repair function of inflammatory cells.
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Summary: In 2011, a total of 330,000 (280,000–390,000) children 
acquired HIV infections predominantly during pregnancy, delivery, 
or breastfeeding in Africa,1 emphasizing the urgent need of effec-
tive strategies to prevent mother-to-child transmission of HIV-1 
(PMTCT). Several medicines and dosing regimens have been sug-
gested as PMTCT. Studies about these prevention strategies suffer 
from several constraints: due to resource limitations and to ethical 
reasons, intensive sampling is not feasible, typically resulting in a 
very sparse data situation. Hence, concepts capable of dealing with 
these situations seem very attractive: Pharmacometrics as an emerg-
ing science based on a transdisciplinary approach bridging ideas of 
biology, pharmacology, clinical pharmacy and pharmacology, medi-
cine, mathematics, and statistics represents an attractive framework 
to understand drug–patient interactions for optimizing prevention or 
treatment strategies. In detail, pharmacokinetic/pharmacodynamic/
biomarker/disease modeling by the population approach aims to elu-
cidate the mechanism-based relationships between dose exposure/
response while incorporating knowledge of the patients and their 
disease.2
In the presentation, the population analysis approach, its ben-
efits, and limitations will be explained and illustrated by an inves-
tigation of a PMTCT program containing nevirapine (NVP).3 For 
NVP: (1) the developed integrated pharmacokinetic model after 
oral administration to pregnant women and their newborns as well 
as derived stratified dosing strategies for different newborns will 
be demonstrated; and (2) how these concentration–time profiles 
of NVP were integrated into a stochastic model of HIV dynam-
ics (including the viral cycle in host cells) and transmission. Based 
on the final model, HIV transmission rates were predicted for a 
2-year period after birth which excellently agreed with data from 
7 independent PMTCT trials. Moreover, new mechanistic insights 
into transplacental transmission as well as resistance were gained, 
both with respect to the underlying NVP concentration–time pro-
files in pregnant women/mothers and newborns. The framework 
developed contributes to improve and guide PMTCT strategies in 
NVP prophylaxis regimens and more importantly in antiretroviral 
combination regimens.
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